26th week of 2015 patent applcation highlights part 24 |
Patent application number | Title | Published |
20150175598 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES AS FUNGICIDES - Heteroarylpiperidine and -piperazine derivatives of the formula (I) in which the symbols A, X, Y, L | 2015-06-25 |
20150175599 | FAAH Inhibitors - The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders. Compounds of the invention are described in Table 1. | 2015-06-25 |
20150175600 | 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS - Compounds of formula (I): | 2015-06-25 |
20150175601 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described. | 2015-06-25 |
20150175602 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 - The present invention provides compounds of formula I: | 2015-06-25 |
20150175603 | TRICYCLIC COMPOUNDS AS KAT II INHIBITORS - Compounds of Formula (I), wherein R | 2015-06-25 |
20150175604 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS - The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer. | 2015-06-25 |
20150175605 | PROCESS METHODS FOR PHOSPHATIDYLINOSITOL 3-KINDASE INHIBITORS - A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed. | 2015-06-25 |
20150175606 | POLYMORPHIC FORMS OF A HYDROCHLORIDE SALT OF (S)-2-(1-(9H-PURIN-6-YLAMINO)PROPYL)-5-FLUORO-3-PHENYLQUINAZOLIN-4(3H)-ON- E - Polymorphs of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed. Solvent forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are also disclosed. | 2015-06-25 |
20150175607 | P62-ZZ CHEMICAL INHIBITOR - A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound. | 2015-06-25 |
20150175608 | NOVEL 4-SUBSTITUTED 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS - The present invention is concerned with novel 4-substituted 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with benzimidazoles having formula (I) | 2015-06-25 |
20150175609 | TREATING DIABETES WITH DIPEPTIDYL PEPTIDASE-IV INHIBITORS - The present invention is directed to novel substituted dihydropyrrolopyrazoles of structural Formula I which are inhibitors of the dipeptidyl peptidase-N enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase IV enzyme is involved. | 2015-06-25 |
20150175610 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE - Pyrazolo[1,5-a]pyrimidine-based compounds of the formula: | 2015-06-25 |
20150175611 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF - The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) | 2015-06-25 |
20150175612 | CRYSTAL FORMS - The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (°2θ) of 6.0, 6.7, 10.4, 11.9, 17.5, 17.7, 21.5, 22.0, 22.7, and 24.2. | 2015-06-25 |
20150175613 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES - The present invention provides compounds of Formula A: | 2015-06-25 |
20150175614 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF - This invention provides compounds of formula (I): | 2015-06-25 |
20150175615 | (6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-(methyl)-2-(prop- -2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound - A compound represented by formula (1) or pharmaceutically acceptable salt thereof: | 2015-06-25 |
20150175616 | SYK INHIBITORS - The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: | 2015-06-25 |
20150175617 | FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS - Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof. | 2015-06-25 |
20150175618 | NEW ANTIFIBRINOLYTIC COMPOUNDS - It relates to spirocyclic compounds of formula (I), or pharmaceutically or veterinary acceptable salts thereof, or any stereoisomers either of the compounds of formula (I) or of their pharmaceutically or veterinary acceptable salts, wherein A and B form a spirocyclic ring system wherein the spiro atom connecting A and B is a carbon atom and wherein A is a known 3- to 8-membered carbocyclic or heterocyclic monocyclic ring or a known 6- to 18-membered carbocyclic or heterocyclic polycyclic ring system; B is a known 4- to 7-membered carbocyclic or heterocyclic monocyclic ring; C is phenyl or a known 5- to 6-membered heteroaromatic ring; and R | 2015-06-25 |
20150175619 | SUBSTITUTED PYRAZOLES AND USES THEREOF - The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. | 2015-06-25 |
20150175620 | COMPOUNDS USEFUL IN THE SYNTHESIS OF HALICHONDRIN B ANALOGS - In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate. Exemplary compounds are of formula (I), (II), or (III): | 2015-06-25 |
20150175621 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES - Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds. | 2015-06-25 |
20150175622 | 3-O-HETEROARYL-INGENOL - The present invention relates to a compound according to formula (I) wherein R | 2015-06-25 |
20150175623 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I): | 2015-06-25 |
20150175624 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES - The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, | 2015-06-25 |
20150175625 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND - Crystalline forms of the anti-HCV compound (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (Compound I) were prepared and characterized in the solid state: | 2015-06-25 |
20150175626 | SYNTHESIS OF AN ANTIVIRAL COMPOUND - The present disclosure provides processes for the preparation of a compound of formula I: | 2015-06-25 |
20150175627 | POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. | 2015-06-25 |
20150175628 | IMIDAZO-OXADIAZOLE AND IMIDAZO-THIADIAZOLE DERIVATIVES - The present invention provides compounds of Formula (I) used as Amyloid beta lowering agent for the treatment of neurodegenerative diseases. | 2015-06-25 |
20150175629 | STRONTIUM PRECURSOR, METHOD FOR PREPARING SAME, AND METHOD FOR FORMING THIN FILM BY USING SAME - Disclosed herein is a novel strontium precursor containing a beta-diketonate compound. Being superior in thermal stability and volatility, the strontium precursor can form a quality strontium thin film. | 2015-06-25 |
20150175630 | ZINC OXIDE COMPLEXES - Disclosed are compounds and methods of making said compounds comprising a zinc oxide molecule chemically bound to one or more molecules having an acidic hydrogen, such as an organic acid. The invention also provides compositions comprising such compounds and methods of preparing such compounds. The compounds of the invention may be provided in, for example, topical skin formulations, pharmaceutical compositions, or delivery systems for active ingredients. | 2015-06-25 |
20150175631 | Gallium Complexes, Pharmaceutical Compositions and Methods of Use - The present invention provides complexes of gallium with a ligand, methods of making the complexes, methods of using the complexes and pharmaceutical gallium compositions comprising the complexes, in particular those compositions suitable for therapeutic oral administration. | 2015-06-25 |
20150175632 | METHOD FOR PRODUCING DIFLUORO ESTER COMPOUND - To provide a method for producing a difluoro compound highly selectively in good yield without forming a hardly soluble by-product. An ester compound of the formula (1) is reacted and fluorinated with an electrophilic fluorinating agent in the presence of a basic compound and in the absence of a metal compound reactant to produce a difluoro ester compound of the formula (2). | 2015-06-25 |
20150175633 | NANO STRUCTURE - Provided are a nano structure, a fabrication method thereof, and an application device using the same. The nano structure includes: a substrate; a plurality of linkers formed over the substrate; and one or more metallic nanoparticles grown from a plurality of metal ions bonded to the linkers. In the nano structure, metallic nanoparticles may have an average particle diameter of about 0.5 to 3.0 nm. | 2015-06-25 |
20150175634 | Preparation of Phenol- or Thiophenyl-Sulfonic Acid Functionalized Solid Acids - Some aryl sulfonic acid-functionalized solids were prepared by a new method. The catalytic activities of esterification by the prepared aryl sulfonic acid-functionalized solids were also tested. | 2015-06-25 |
20150175635 | METHOD FOR THE SYNTHESIS OF N-(PHOSPHONOMETHYL)GLYCINE - The present invention is related to a new method for the synthesis of N-(phosphonomethyl)glycine or one of its derivatives selected from the group consisting of its salts, its phosphonate esters and its phosphonate ester salts, comprising the steps of: a) forming a reaction mixture comprising an acid catalyst, N,N′-bis(carboxymethyl)-2,5-diketopiperazine and a compound comprising one or more P—O—P anhydride moieties, wherein said moieties comprise one P atom at the oxidation state (+111) and the other P atom at the oxidation state (+111) or (+V), to form N,N′-bis(phosphonomethyl)-2,5-diketopiperazine, its dehydrated forms or their phosphonate esters; b) hydrolyzing the reaction mixture to form N-(phosphonomethyl)glycine or one of its derivatives selected from the group consisting of its salts, its phosphonate esters and its phosphonate ester salts. | 2015-06-25 |
20150175636 | METHOD FOR THE SYNTHESIS OF N-(PHOSPHONOMETHYL)GLYCINE - A method for the synthesis of N-(phosphonomethyl)glycine or one of its derivatives selected from the group consisting of its salts, its phosphonate esters, or its phosphonate ester salts, which includes the steps of: a) forming, in the presence an acid catalyst, a reaction mixture having 2,5-diketopiperazine, formaldehyde and a compound including one or more P-0-P anhydride moieties, the moieties having one P atom at the oxidation state (+III) and the other P atom at the oxidation state (+III) or (+V), to form N,N′-bisphosphonomethyl-2,5-diketopiperazine, its mono- to tetra phosphonate esters, the dehydrated forms of N,N′-bisphosphonomethyl-2,5-diketopiperazine and the phosphonate esters of its dehydrated forms; and b) hydrolysing the N,N′-bisphosphonomethyl-2,5-diketopiperazine, its dehydrated forms or their phosphonate esters to obtain N-(phosphonomethyl)glycine or one of its derivatives selected from the group consisting of its salts, its phosphonate esters and its phosphonate ester salts. | 2015-06-25 |
20150175637 | OLIGOMER-FOSCARNET CONJUGATES - The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds. | 2015-06-25 |
20150175638 | PROCESS FOR THE PREPARATION OF PHOSPHONIUM SULFONATES - The invention relates to a process for the preparation of phosphonium sulfonates, particularly tetraalkylphosphonium fluoroalkylsulfonates, in the presence of amine-type bases. | 2015-06-25 |
20150175639 | Pharmaceutical Process and Intermediates - The present disclosure provides for processes and intermediates in the large-scale manufacture of the compound of formula (I) or hydrates thereof. | 2015-06-25 |
20150175640 | FORMS OF CIDOFOVIR - Cidofovir is obtained in different forms, including amorphous cidofovir, crystalline anhydrous cidofovir, crystalline cidofovir monohydrate, and crystalline cidofovir dihydrate, including various polymorphs. | 2015-06-25 |
20150175641 | PHOSPHORAMIDIC ACID PRODRUGS OF 5-[5-PHENYL-4-(PYRIDIN-2-YLMETHYLAMINO)QUINAZOLIN-2-YL]PYRIDINE-3-SULFONA- MIDE - A compound of structural formula (I), wherein R is H or —PO3H or a pharmaceutically acceptable salt form thereof. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, I | 2015-06-25 |
20150175642 | METAL ALKOXIDE COMPOUND, THIN-FILM-FORMING MATERIAL, METHOD FOR PRODUCING THIN FILM, AND ALCOHOL COMPOUND - Disclosed is a metal alkoxide compound having physical properties suitable for a material for forming thin films by CVD, and particularly, a metal alkoxide compound having physical properties suitable for a material for forming metallic-copper thin films. A metal alkoxide compound is represented by general formula (I). A thin-film-forming material including the metal alkoxide compound is described as well. (In the formula, R | 2015-06-25 |
20150175643 | OLIGOSACCHARIDE-PROTEIN CONJUGATES - Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate. | 2015-06-25 |
20150175644 | MANNOSE DERIVATIVES AS ANTAGONISTS OF BACTERIAL ADHESION - Compounds of the formula (I) wherein n is 0, 1 or 2, R | 2015-06-25 |
20150175645 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF - Provided herein are sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. | 2015-06-25 |
20150175646 | SOLID FORMS OF AN ANTIVIRAL COMPOUND - Crystalline solid forms of the anti-HCV compound (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate (Compound I) are described | 2015-06-25 |
20150175647 | SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PRODRUG - The present application relates to solid state forms, for example, crystalline forms of 2′-C-methyluridine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2′-C-methyluridine-5′-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents. | 2015-06-25 |
20150175648 | HCV POLYMERASE INHIBITORS - The invention provides compounds of the formula: | 2015-06-25 |
20150175649 | SYNTHETIC pGpG ANALOGS, METHODS OF PREPARATION AND METHODS OF USE - The present invention relates to compounds according to Formula I: and salts thereof, wherein R | 2015-06-25 |
20150175650 | SYNTHESIS OF ENT-PROGESTERONE AND INTERMEDIATES THEREOF - The present invention relates to the synthesis of ent-progesterone and intermediates thereof. | 2015-06-25 |
20150175651 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF - Described herein are neuroactive steroids of the Formula (1) or a pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, and/or isotopic variant thereof. Such compounds are envisioned, in certain embodiments, to behave as soft drugs and, in certain embodiments, as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia. | 2015-06-25 |
20150175652 | METHOD OF PURIFYING/CONCENTRATING SUGAR CHAINS WITH A SUGAR CHAIN-TRAPPING MOLECULE AND METHOD OF ANALYZING SUGAR CHAIN STRUCTURE - The present invention provides substance which can specifically interact with sugar chains. Further, the present invention provides a method for separating, concentrating, or purifying sugar chains or a sugar chain-containing substance in a sample, comprising the steps of: a) contacting a sugar chain-trapping carrier comprising a substance which can specifically interact with sugar chains with the sample in a fluid phase under conditions that the sugar chain-trapping carrier can react with the sugar chains or sugar chain-containing substance; b) isolating a composite of the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance from the fluid phase; and c) exposing the composite to the conditions that the interaction between the sugar chain-trapping carrier and the sugar chains or sugar chain-containing substance is at least partially eliminated. | 2015-06-25 |
20150175653 | CRYSTALLINE OXIDIZED GLUTATHIONE AND PRODUCTION METHOD THEREFOR - Provided is a novel crystal of oxidized glutathione hexahydrate. Crystal of oxidized glutathione hexahydrate is produced by cooling an aqueous solution containing oxidized glutathione to 15° C. or lower to precipitate a crystal of oxidized glutathione hexahydrate. | 2015-06-25 |
20150175654 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE COMPRISING THE PEPTIDE HAVING THE ABILITY TO INHIBIT ANGIOTENSIN-1 CONVERTING ENZYME AS AN ACTIVE INGREDIENT - The present invention relates to a peptide separated from the fraction of oyster enzyme hydrate displaying the ability of suppressing angiotensin converting enzyme (ACE) and a pharmaceutical composition for the prevention and treatment of cardiovascular disease comprising the said peptide as an active ingredient. Particularly, the peptide separated from the fraction of the oyster enzyme hydrate of the present invention significantly inhibits ACE activity, and thus brings blood pressure regulating effect and antihypertensive effect. Therefore, the fraction of the oyster enzyme hydrate of the invention or the peptide separated from the same can be effectively used as an active ingredient of a pharmaceutical composition for the prevention or treatment of cardiovascular disease. | 2015-06-25 |
20150175655 | INHIBITORS OF HEPATITIS C VIRUS - Compounds of Formula I are disclosed, As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed. | 2015-06-25 |
20150175656 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS - The invention relates to crystalline tripeptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. | 2015-06-25 |
20150175657 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2015-06-25 |
20150175658 | INDUCTION OF TUMOR IMMUNITY BY VARIANTS OF FOLATE BINDING PROTEIN - The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness. | 2015-06-25 |
20150175659 | Peptide Derivatives as Antibiotics - The present invention relates to antibiotic compounds, methods for producing said compounds, pharmaceutical compositions comprising said compounds, and methods of treatment comprising administering said compounds and/or compositions comprising said compounds. | 2015-06-25 |
20150175660 | CONTROLLED MODULATION OF AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGENS - The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens. | 2015-06-25 |
20150175661 | GPCR WITH IMPROVED CELL SURFACE EXPRESSION - The present invention surprisingly shows that the addition of a heterologous viral-GPCR (G protein-coupled receptor) derived sequence at the amino terminal end of GPCRs improves cell surface expression of such receptors in eukaryotic cells. Transfected cells expressing the above heterologous viral GPCRs on their surface are useful for cell based assays to identify test compounds that increases or modulate activity of a GPCR or a ligand of a GPCR for example for drug discovery, development of novel flavors in the food industry or development of sensors based on odor GPCRs. In addition, membrane extracts derived from transfected cells may be used for example for assays of compounds in drug discovery or for development of sensors comprising such membrane extracts for identification and/or quantification of volatile organic compounds. | 2015-06-25 |
20150175662 | NOVEL PEPTIDES AND USE THEREOF - The present invention relates to novel peptides and use thereof and more specifically is directed to a peptide with anti-inflammatory effect, a polynucleotide encoding the peptide, a pharmaceutical composition comprising the peptide or polynucleotide for preventing or treating inflammatory diseases, an anti-inflammatory drug, an over-the-counter (OTC) drug composition comprising the peptide for preventing or ameliorating inflammation, a health food composition for alleviating or ameliorating inflammation, a cosmetic composition for preventing or ameliorating inflammation, a method for treating inflammatory diseases, comprising administrating the pharmaceutical composition to the subject suspected of having inflammatory disease, a method for preparing a mimetic of the peptide and a method for designing the same. | 2015-06-25 |
20150175663 | Process for Producing Self-Assembling Peptide Derivatives - An object of the present invention is to provide a process capable of producing a self-assembling peptide derivative that is useful in the fields of regenerative medicine and surgery in large quantities and in an economical and efficient manner. In particular, provided is a production process employing a combination of (i) a step of convergently constructing a sequence with use of a common repeating unit consisting of a specific amino acid sequence and (ii) a step of first isolating the peptide derivative as a disulfuric acid salt, a tetramethanesulfonic acid salt or a tetra(trifluoroacetic acid (TFA) salt), and then subjecting the peptide salt to a salt exchange reaction to yield a tetrahydrochloric acid salt. | 2015-06-25 |
20150175664 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS - Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X | 2015-06-25 |
20150175665 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL - There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity. | 2015-06-25 |
20150175666 | PEPTIDES DERIVED FROM HIV GP41 FOR TREATING T-CELL MEDIATED PATHOLOGIES - The present invention provides peptides, derivatives and analogs comprising an amino acid sequence HTTWMEWD (SEQ ID NO: 1) derived from the ectodomain of HIV gp41 protein, pharmaceutical compositions comprising same, and uses thereof for therapy of T-cell mediated diseases and disorders. | 2015-06-25 |
20150175667 | TARGETED GENE DELIVERY FOR DENDRITIC CELL VACCINATION - Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers. | 2015-06-25 |
20150175668 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 2015-06-25 |
20150175669 | Novel Peptide Tag and Uses Thereof - There are provided peptide tags derived from bacteriophytochrome (BphP) that is photoreceptor protein of | 2015-06-25 |
20150175670 | FUSION PROTEINS AND COMBINATION VACCINES COMPRISING HAEMOPHILUS INFLUENZAE PROTEIN E AND PILIN A - The present invention relates to compositions comprising | 2015-06-25 |
20150175671 | OIL GLOBULE PROTEIN AND USES THEREOF - An isolated novel oil globule protein encoded by a polynucleotide sequence is provided together with a composition which includes the isolated protein. A transgenic organism transformed by a polynucleotide encoding a protein which at least partially comprises the amino acid sequence of the novel oil globule protein is also provided. The invention also provides a method for producing or enhancing the production of a carotenoid such as astaxanthin, which is an oil globule constituent. | 2015-06-25 |
20150175672 | PROCESS FOR DESIGNING DIVERGED, CODON-OPTIMIZED LARGE REPEATED DNA SEQUENCES - This disclosure concerns methods for the design of synthetic nucleic acid sequences that encode polypeptide amino acid repeat regions. This disclosure also concerns the use of such sequences to express a polypeptide of interest that comprises amino acid repeat regions, and organisms comprising such sequences. | 2015-06-25 |
20150175673 | COMPOSITION FOR PREVENTING OR TREATING FRACTURE OR OSTEOPOROSIS USING SLIT-ROBO SYSTEM - A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis. | 2015-06-25 |
20150175674 | LIPIDATED PEPTIDES AS ANTI-OBESITY AGENTS - Lipidated peptides, analogs of both forms of the prolactin-releasing peptide, PrRP31 and PrRP20, represent anorexigenic compounds that lower food intake and function in the brain after peripheral administration. The analogs PrRP31 and PrRP20 lipidated at the N-terminus by myristic or palmitic acids bind with high affinity to the endogenous receptor GPR10 in the rat pituitary cell line RC-4B/C and CHO cell line with transfected human receptor. These lipidated peptides also significantly decrease, in a dose-dependent manner, the food intake in fasted mice and have similar effects in comparable doses as centrally administered natural PrRP31, these effects are, however, stronger and longer lasting. Lipidation of an effective anorexigenic neuropeptide PrRP induces a central effect after peripheral administration and thus makes the lipidated analogs of PrRP a promising anti-obesity drug. | 2015-06-25 |
20150175675 | FUSION POLYPEPTIDES AND METHODS OF USE THEREOF - The present invention also provides fusion polypeptides with a carboxy-terminal or N-terminal peptide domain (e.g., Fc, CTP, or Fc-CTP), and nucleic acid molecules encoding these polypeptides. The present invention further provides for methods of using the compositions of the invention for treatment of cancer and fibrotic diseases. The present invention also provides isolated polypeptides with a carboxy-terminal peptide (CTP) domain fused to an antibody fragment, and nucleic acid molecules encoding these polypeptides. The present invention also provides isolated polypeptides with a carboxy-terminal peptide (CTP) domain fused to the ectodomain of a receptor, and nucleic acid molecules encoding these polypeptides. Also provided are isolated fusion polypeptide molecules, with an isolated polypeptide attached to a carboxy terminus of a second polypeptide, and to nucleic acid molecules encoding these isolated fusion polypeptide molecules. Finally, methods of increasing a biological half-life of a polypeptide, methods of stabilizing a polypeptide, pharmaceutical compositions including the polypeptides and fusion polypeptides, and methods of treating or preventing a disorder using these polypeptides are provided | 2015-06-25 |
20150175676 | Fusion Polypeptides Capable Of Activating Receptors - A fusion polypeptide comprising (A) | 2015-06-25 |
20150175677 | HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H3N2 AND USES THEREOF - Described are binding molecules, e.g., human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, e.g., H3N2, and have a broad neutralizing activity against such influenza virus. Described are polynucleotides encoding the binding molecules, their sequences and compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of influenza virus H3N2 infection. The binding molecules may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated. | 2015-06-25 |
20150175678 | IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME - The present invention relates to isolated IgA antibodies, or fragments thereof, which have variable domains derived from an antibody that specifically binds to a CD4-induced (CD4i) epitope. In particular, the isolated IgA antibodies display enhanced neutralization activity relative to their IgG, non-chimeric counterparts. The invention also provides methods for therapy with the isolated IgA antibodies for the treatment of a subject having a viral infection or having an increased risk of a viral infection. | 2015-06-25 |
20150175679 | HIV-1 PEPTIDES, NUCLEIC ACIDS, AND COMPOSITIONS, AND USES THEREOF - This invention features polypeptides, variants thereof, and fragments thereof useful in eliciting an immune response (e.g., neutralizing antibodies) against a broad spectrum of HIV-1 isolates. The polypeptides, variants, and fragments include a portion of the gp120 V2 domain of HIV-1. The polypeptides, variants, and fragments display an epitope that is recognized by at least one antibody which neutralizes at least one HIV-1 primary isolate. This invention also features nucleic acid sequences encoding those polypeptides. In addition, the invention provides methods of screening for inhibitors of HIV-1 entry into cells, as well as methods of treatment using the inhibitors. | 2015-06-25 |
20150175680 | HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE - The invention described herein provides for human antibodies produced in non-human animals that specifically bind to | 2015-06-25 |
20150175681 | ANTIBODIES FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED INFECTION AND DISEASE - Provided herein are reagents, compositions, and therapies with which to treat | 2015-06-25 |
20150175682 | HUMANIZED TAU ANTIBODY - The present invention provides, methods end composites for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with neurofibrillary tangles. In particular, the Invention relates to humanized antibodies, which specifically recognize and bind to phosphorylated pathological protein tau-conformers to methods and compositions involving antibodies for the therapeutic and diagnostic use In the treatment of tauopathies including Alzheimer's Disease (AD). | 2015-06-25 |
20150175683 | BINDING MOLECULES TARGETING PATHOGENS - A first aspect of the disclosure relates to the field of binding molecules targeted at pathogens. The disclosure further relates to proteinaceous binding molecules targeting cells displaying pathogen-associated molecular patterns, in particular targeting cell surface molecules associated with or derived from pathogens, more in particular cell surface proteins displaying peptides from intracellular (pathogen associated) proteins. | 2015-06-25 |
20150175684 | Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES - The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto. | 2015-06-25 |
20150175685 | HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE - The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same. | 2015-06-25 |
20150175686 | Monoclonal Antibodies for Treatment of Cancer - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer. | 2015-06-25 |
20150175687 | MYOSTATIN BINDING AGENTS - The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity. | 2015-06-25 |
20150175688 | PRODUCTION CELL LINE ENHANCERS - The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture. | 2015-06-25 |
20150175689 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 2015-06-25 |
20150175690 | MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS - Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase. | 2015-06-25 |
20150175691 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 2015-06-25 |
20150175692 | ANTI-IL-17A ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17A antagonists (inhibit the activities of IL-17A and IL-17AF) and are capable of inhibiting IL-17A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders. | 2015-06-25 |
20150175693 | NOVEL IL-3 ANTIBODIES AND THEIR USE IN DIAGNOSIS AND TREATMENT OF DISEASES OR MALFUNCTIONS ASSOCIATED WITH ELEVATED LEVELS OF IL-3 - Novel anti-IL-3 antibodies or fragments or constructs thereof according to the present invention specifically bind to an epitope contained within the N-terminal 20 amino acids of the amino acid sequence of human IL-3 according to SEQ ID No. 1, and preferably to a sequence motif SWVN. The antibodies can be used in diagnostic methods for the determination of IL-3 levels in body fluids, preferably in corresponding ELISA assays, but also in pharmaceutical compositions for the treatment or prevention of diseases which are associated with elevated levels of IL-3 in a patient, especially rheumatoid arthritis. | 2015-06-25 |
20150175694 | DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING - Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1α and IL-1β) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1α and/or IL-1β activity is detrimental. | 2015-06-25 |
20150175695 | RAC1 INHIBITORS FOR THE TREATMENT OF ALPORT GLOMERULAR DISEASE - The present invention provides methods of treating Alport syndrome in a subject by the administration of an agent that can blocks the activation of RAC1/CDC42 members of the rho family of small GTPases. Such agents include, but are not limited to, the endothelin receptor antagonists such as bosentan and letairis and neutralizing antibodies to endothelin-1. Such administration prevents invasion of the glomerular capillary tufts by mesangial lamellipodial/filopodial processes, blocks mesangial process invasion abrogates the deposition of laminin 211 in the GBM, and prevents the activation of maladaptive expression of proteins known to contribute to glomerular disease progression. | 2015-06-25 |
20150175696 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2015-06-25 |
20150175697 | Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life - The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein. The invention also pertains to methods and uses that employ such molecules. | 2015-06-25 |